Weight loss
The scale of weight loss seen in trials is the main reason tirzepatide has attracted so much attention.
Explore the research →DUAL GIP / GLP-1 RESEARCH & THERAPY
Tirzepatide
A leading medicine in diabetes and weight management, tirzepatide has strong human evidence for blood-sugar control, reduced appetite and substantial weight loss.
Weight managementGlucose controlAppetite
Extensive human evidenceLarge randomized trial programmes show substantial effects on body weight and glycaemic control, with safety patterns dominated by gastrointestinal adverse effects.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why has Tirzepatide attracted so much attention?
Tirzepatide has become one of the biggest names in weight management because it can reduce appetite, improve blood-sugar control and lead to substantial weight loss. Its two-hormone approach is a big part of the interest, bringing together effects on hunger, fullness and metabolism.
Type 2 diabetes
Tirzepatide also has a substantial evidence base for improving blood-sugar control in people with type 2 diabetes.
Explore the research →Appetite & feeling full
Reduced hunger and feeling satisfied with less food are central to the way tirzepatide supports weight loss.
Explore the research →Wider metabolic health
The interest goes beyond the number on the scales, with studies also tracking waist size, blood pressure, cholesterol and other markers of metabolic health.
Explore the research →THE SCIENCE BIT
Two hormone pathways working together.
Tirzepatide activates receptors for both GIP and GLP-1. These are hormones involved in the response to food, and their combined signalling affects insulin release, appetite and metabolic regulation.
It is one engineered molecule with two receptor targets. Human trials measure how that design translates into glucose control and weight loss.
See the studies & trials →- GIPR
- Nutrient and insulin signalling
- GLP-1R
- Appetite and glucose control
- Combined action
- Two targets in one molecule
How this connects to the research
Established dual-receptor pharmacology and substantial human evidence.
FROM MOLECULE TO TISSUE
Where Tirzepatide connects with the body
These are the tissues and biological systems behind the interest in Tirzepatide.
- Pancreas
- Glucose-dependent insulin release.
- Brain and gut
- Appetite and fullness.
- Metabolic tissues
- Nutrient-handling research.
The research behind the interest
Weight loss
The scale of weight loss seen in trials is the main reason tirzepatide has attracted so much attention.
Large obesity trials have reported substantial average weight reductions across the studied doses compared with placebo.
Strong human evidenceExplore the studies →Type 2 diabetes
Tirzepatide also has a substantial evidence base for improving blood-sugar control in people with type 2 diabetes.
Trials show large reductions in HbA1c together with improvements in fasting and after-meal glucose levels.
Strong human evidenceExplore the studies →Appetite & feeling full
Reduced hunger and feeling satisfied with less food are central to the way tirzepatide supports weight loss.
Its effects on the body's appetite-regulating hormone systems are consistent with the substantial reductions in food intake and body weight seen in clinical studies.
Strong human & mechanistic evidenceExplore the studies →Wider metabolic health
The interest goes beyond the number on the scales, with studies also tracking waist size, blood pressure, cholesterol and other markers of metabolic health.
Many trials report improvements across several of these measures alongside the reduction in body weight.
Strong supporting human evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableTirzepatide Once Weekly for the Treatment of Obesity ↗
2,539 adults with obesity or overweight plus a weight-related complication, without diabetes
SubcutaneousOnce weekly72 weeks
Tirzepatide produced substantial and sustained weight reduction across the 5 mg, 10 mg and 15 mg groups compared with placebo.
The most common adverse events were gastrointestinal and were mostly mild to moderate, particularly during dose escalation.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceExtensive
5/5 evidence depth
✓
Clinical efficacyExtensive
5/5 evidence depth
This score reflects completed human outcome evidence. A registered or recruiting trial does not count until results are reported.
◇
Safety evidenceStrong
4/5 evidence depth
⌁
Preclinical evidenceStrong
4/5 evidence depth
HOW TO READ THESE SCORESStrong preclinical evidence · extensive human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE EVIDENCE IS ORGANISED
Tirzepatide research profile
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
RESEARCH AREA 01Weight management
RESEARCH AREA 02Glucose control
RESEARCH AREA 03Appetite
RESEARCH AREA 04Metabolic health
Mechanistic and preclinical findings are context for further research; they are not treated as equivalent to demonstrated human outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Tirzepatide
People most often discuss tirzepatide around reduced appetite, substantial weight change, quieter food thoughts and the practical challenge of balancing results with gastrointestinal tolerability. Those experiences sit beside one of the strongest human evidence bases on the site.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Quieter appetite without constant negotiation
The desired change is often fewer intrusive food thoughts, less snacking and smaller portions that feel sufficient. People distinguish this relief from simply losing interest in all food.
- What makes a report informative
- Cravings, hunger and satisfaction after meals.
- What can muddy the picture
- Previous GLP-1 use and gastrointestinal symptoms can shape the experience.
Progress when weight has been difficult to shift
Interest includes sustained weight loss and changes in waist or mobility. Comparisons with semaglutide attract attention, although switching stories are rarely controlled comparisons.
- What makes a report informative
- Weight and waist trends alongside everyday movement.
- What can muddy the picture
- Starting weight, treatment history and concurrent lifestyle changes affect comparisons.
Better metabolic health with tolerable treatment
For some people the goal includes glucose control as well as weight. Others focus on whether reduced appetite can coexist with energy, adequate meals and comfortable digestion.
- What makes a report informative
- Relevant clinical measurements and day-to-day food tolerance.
- What can muddy the picture
- Feeling better cannot substitute for glucose measurements or establish a separate metabolic effect.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Less hunger and earlier fullness
Human findings & limits
Large randomized trials show substantial average weight loss, while the authorised product information recognises reduced appetite as part of the treatment effect.
Laboratory & animal context
Dual GIP and GLP-1 receptor activity affects appetite, glucose-dependent insulin release and wider metabolic signalling.
What this means: A well-supported human effect, although the strength and day-to-day experience vary.
Large weight loss over time
Human findings & limits
SURMOUNT-1 found substantial average weight reduction over 72 weeks across the studied maintenance doses.
Laboratory & animal context
The biological rationale is strong, but it cannot predict one person’s final result or the timing of a plateau.
What this means: Strongly supported for approved populations; individual pace and total loss remain variable.
Nausea, bowel change and dose-step decisions
Human findings & limits
Nausea, diarrhoea, vomiting, abdominal pain and constipation are well described, particularly around dose increases.
Laboratory & animal context
Effects on appetite and gastrointestinal function make tolerability part of the same pharmacology that supports benefit.
What this means: A recognised practical issue. More side effects do not mean a better response.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
Licensed tirzepatide dosing uses gradual escalation; exact clinical dosing depends on indication, tolerability and prescribing guidance.
PUBLISHED HUMAN RESEARCH
View source ↗SURMOUNT-1 obesity trial ↗
Adults with obesity or overweight without diabetes
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved Adults with obesity or overweight without diabetes. Route: Injection under the skin (SubQ). The study lasted 72 weeks. The figures below describe the research design, not a personal schedule.
| First amount studied | 2.5 mg weekly |
|---|---|
| Later or target amount | 5 mg, 10 mg or 15 mg weekly target groups |
| How often? | once a week |
| How was it given? | Injection under the skin (SubQ) |
| How long? | 72 weeks |
See the exact study wording +
Start / initial: 2.5 mg weekly
End / target: 5 mg, 10 mg or 15 mg weekly target groups
Frequency: Once weekly
Route: Subcutaneous
Study duration: 72 weeks
Phase 3 trial protocol; not personalised dosing advice.
PRACTICAL DOSING CONTEXT
Licensed schedule context · prescription medicineHow the authorised schedule is structured
STARTING APPROACHES
The authorised schedule starts at 2.5 mg once weekly for four weeks before moving to 5 mg once weekly. It is a licensed starting schedule, not a personalised target.
DURATION / CYCLES
Further increases use 2.5 mg steps and are separated by at least four weeks. The appropriate maintenance dose depends on response, tolerability and current prescribing information.
MAINTENANCE DISCUSSION
5 mg, 10 mg and 15 mg once weekly are the principal maintenance doses in current product information; 15 mg is the maximum weekly dose.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
UK licensed starting sequence
UK product informationCurrent UK product information starts at 2.5 mg once weekly and moves to 5 mg after four weeks. Later increases are conditional and are therefore not automatically built into this editable starting template.
Form and route: Weekly subcutaneous injection
| Calendar stage | Amount each time |
|---|---|
| Weeks 1–4 | 2.5 mg |
| Then onwards | 5 mg |
Frequency: Once weekly · 1 entry per scheduled day.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Safety context
SAFETY & UNCERTAINTY
A strong human safety record still needs prescription-level care
What the current evidence saysGastrointestinal effects are common, especially after dose increases. Current product information also covers hypoglycaemia risk with insulin or sulphonylureas, pancreatitis, gallbladder problems, dehydration and situations where treatment may not be suitable.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Why this matters
Persistent vomiting, severe abdominal pain, dehydration or symptoms of low blood sugar need prompt clinical advice. Unapproved or inaccurately compounded products add separate concentration and quality risks.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
5 sourcesSources used on this profile
Peer-reviewed human trialTirzepatide Once Weekly for the Treatment of ObesityNEJM ↗Original publicationTirzepatide Once Weekly for the Treatment of ObesityJournal / DOI ↗Bibliographic recordTirzepatide Once Weekly for the Treatment of ObesityPubMed ↗Trial registryTirzepatide Once Weekly for the Treatment of ObesityClinicalTrials.gov ↗Current official product informationSafety and uncertaintyEMA · Mounjaro ↗
CURRENT STATUS
How to interpret its position today
Authorised prescription medicine
Tirzepatide is authorised for defined type 2 diabetes and weight-management indications. The current product information governs dose escalation, contraindications and monitoring.
EMA · Mounjaro ↗Large randomized programmes
Weight-management and diabetes outcomes have been studied in large human trials; those findings apply to the tested products, populations and protocols.
SURMOUNT-1 · PubMed ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.